prolaio eVO2peak Module vs ElucidVivo A.3
AI Verdict
Choose prolaio eVO2peak Module if…
Choose Prolaio eVO2peak Module if you need to non-invasively estimate peak oxygen consumption and monitor cardiovascular functional capacity using real-world patient data from wearable sensors. This tool is ideal for longitudinal tracking of patient fitness and as an adjunctive aid in clinical evaluation, particularly when traditional stress testing may be challenging or less frequent.
View prolaio eVO2peak Module →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography images. This system is best suited for stratifying atherosclerosis patients, identifying vulnerable plaque characteristics, and optimizing treatment decisions based on precise visualization and measurement of plaque components.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | prolaio eVO2peak Module | ElucidVivo A.3 |
|---|---|---|
| Deployment | Cloud | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
prolaio eVO2peak ModuleTool A's cloud-based deployment and reliance on remote, wearable sensor data, coupled with a patient-guiding mobile app, suggests a more streamlined and accessible user experience for continuous monitoring. In contrast, Tool B, while offering advanced imaging analysis, likely requires more specialized workflow integration within a radiology or cardiology department.
Clinical Value
ElucidVivo A.3Tool B offers a more profound and predictive clinical insight by quantifying arterial plaque composition and stability, validated against histology, and deriving FFRct, which directly impacts patient stratification and treatment optimization for atherosclerosis. While Tool A provides valuable eVO2peak estimation, it is positioned as an 'adjunctive aid' in clinical evaluation.
Pricing & Value
TieBoth tools require direct contact for pricing, making it impossible to conduct a head-to-head comparison on this dimension. Without transparent pricing information, assessing their relative value is not feasible.
Enterprise Readiness
prolaio eVO2peak ModuleTool A explicitly states HIPAA compliance, BAA availability, FDA clearance, and further details compliance with 21CFR Part 11, ISO 13485:2016, and MDSAP, providing a comprehensive picture of its enterprise readiness. While Tool B mentions PACS/EMR interoperability and 'HIPAA-aligned data protection', its HIPAA and BAA status are not explicitly stated in the initial facts, making Tool A's claims more robust.
Innovation
ElucidVivo A.3Tool B demonstrates greater innovation by offering quantitative analysis of arterial plaque composition and stability from CT angiography, validated against ground-truth histology, and deriving fractional flow reserve (FFRct). This moves beyond traditional diagnostic assistance to provide predictive insights for personalized atherosclerosis management, which is a more complex and impactful innovation in diagnostic imaging.
Support & Docs
prolaio eVO2peak ModuleProlaio explicitly details 'Always-on support' and a dedicated helpdesk role, indicating a structured and accessible support system for its users and patients. In contrast, ElucidVivo A.3's support and documentation are not as clearly articulated in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | prolaio eVO2peak Module | ElucidVivo A.3 |
|---|---|---|
| Name | prolaio eVO2peak Module | ElucidVivo A.3 |
| Company | Prolaio | Elucid Bioimaging |
| Description | FDA-cleared software to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. |
| Primary Function | Estimates peak oxygen consumption (eVO2peak) | AI-powered quantitative analysis of arterial plaque |
| Key Inputs | Demographic data, single-lead ECG, and triaxial accelerometry inputs from qualified third-party FDA-cleared wearable medical sensors | CT angiography images |
| Specialties | Cardiology, Physical Medicine & Rehab, Sports Medicine | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring prolaio eVO2peak Module and ElucidVivo A.3.